Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Extensive Stage Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Extensive Stage Small Cell Lung Cancer: Overview
Extensive stage small cell lung cancer (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis. Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.
'Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Extensive Stage Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Extensive Stage Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Extensive Stage Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Extensive Stage Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Extensive Stage Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Extensive Stage Small Cell Lung Cancer Emerging Drugs
Further product details are provided in the report……..
Extensive Stage Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Extensive Stage Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Extensive Stage Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Extensive Stage Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Extensive Stage Small Cell Lung Cancer drugs.
Extensive Stage Small Cell Lung Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Extensive Stage Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Extensive Stage Small Cell Lung Cancer: Overview
Extensive stage small cell lung cancer (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis. Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.
'Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Extensive Stage Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Extensive Stage Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Extensive Stage Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Extensive Stage Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Extensive Stage Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Extensive Stage Small Cell Lung Cancer.
This segment of the Extensive Stage Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Extensive Stage Small Cell Lung Cancer Emerging Drugs
- LY 2510924: Eli Lilly and Company
- Tiragolumab: Genentech
Further product details are provided in the report……..
Extensive Stage Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Extensive Stage Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Extensive Stage Small Cell Lung Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Extensive Stage Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Extensive Stage Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Extensive Stage Small Cell Lung Cancer drugs.
Extensive Stage Small Cell Lung Cancer Report Insights
- Extensive Stage Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Extensive Stage Small Cell Lung Cancer drugs?
- How many Extensive Stage Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Extensive Stage Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Extensive Stage Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Extensive Stage Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- Genentech
- Bristol-Myers Squibb
- Henlix Biotech
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- BioNTech SE
- Xencor, Inc.
- Haihe Biopharma Co., Ltd.
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Celgene
- MedImmune
- Xcovery Holding Company, LLC
- Lee's Pharmaceutical Limited
- Merck & Co
- Astex Pharmaceuticals
- LY 2510924
- Tiragolumab
- BMS-986012
- Serplulimab
- SYHA1807
- BNT411
- XmAb18087
- Vorolanib
- AL3810
- LP002
- CC-90011
- Tremelimumab
- Ipilimumab
- ZKAB001
- Pembrolizumab
- Guadecitabine
Introduction
Executive Summary
Extensive Stage Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Tiragolumab: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LY 2510924: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Extensive Stage Small Cell Lung Cancer Key Companies
Extensive Stage Small Cell Lung Cancer Key Products
Extensive Stage Small Cell Lung Cancer- Unmet Needs
Extensive Stage Small Cell Lung Cancer- Market Drivers and Barriers
Extensive Stage Small Cell Lung Cancer- Future Perspectives and Conclusion
Extensive Stage Small Cell Lung Cancer Analyst Views
Extensive Stage Small Cell Lung Cancer Key Companies
Appendix
Executive Summary
Extensive Stage Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Tiragolumab: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LY 2510924: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Extensive Stage Small Cell Lung Cancer Key Companies
Extensive Stage Small Cell Lung Cancer Key Products
Extensive Stage Small Cell Lung Cancer- Unmet Needs
Extensive Stage Small Cell Lung Cancer- Market Drivers and Barriers
Extensive Stage Small Cell Lung Cancer- Future Perspectives and Conclusion
Extensive Stage Small Cell Lung Cancer Analyst Views
Extensive Stage Small Cell Lung Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Extensive Stage Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Extensive Stage Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Extensive Stage Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Extensive Stage Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
